CJC-1295 vs Sermorelin
A comprehensive, data-driven comparison of CJC-1295 (Modified GRF 1-29) and Sermorelin (GHRH 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | CJC-1295 Modified GRF 1-29, DAC:GRF | Sermorelin GHRH 1-29, GRF 1-29 |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Withdrawn (off-label use continues) |
| Category | Growth Hormone | Growth Hormone |
| Primary Use | Growth hormone optimization and anti-aging | Growth hormone deficiency and anti-aging |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $150 - $350/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1-2mg twice weekly (with DAC) | 200-500mcg daily before bed |
| Frequency | Twice weekly | Daily |
| Mechanism | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone | Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Moderate |
| Clinical Trial Phase | N/A | N/A |
Key Differences
- 1CJC-1295 is generally more affordable ($35 - $70/mo) compared to Sermorelin ($150 - $350/mo).
- 2CJC-1295 is dosed twice weekly, while Sermorelin is daily.
- 3Sermorelin has moderate-quality evidence, while CJC-1295 has emerging-quality evidence.
Which Is Better For...
CJC-1295
More budget-friendly option with lower monthly costs
CJC-1295
More convenient dosing schedule (twice weekly)
CJC-1295
Fewer commonly reported side effects
Sermorelin
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| Sermorelin | $150 - $350/mo | Withdrawn (off-label use continues) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. Sermorelin works via Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH. They differ in FDA approval status, efficacy data, and cost.
CJC-1295 typically costs $35 - $70/mo, while Sermorelin costs $150 - $350/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). Sermorelin is not FDA-approved (Withdrawn (off-label use continues)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of Sermorelin include Injection site reactions, Flushing, Headache. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideSermorelin is a bioidentical synthetic version of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of the full 44-amino acid GHRH molecule. It was previously FDA-approved...
View Full Sermorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between CJC-1295 and Sermorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.